Moderna Inc. recorded a quarterly loss as vaccine sales waned and the company had an unexpected charge for a canceled ...

MSD and Moderna have kicked off another phase 3 trial of their personalised cancer vaccine V940 used alongside MSD's PD-1 inhibitor Keytruda, this time focusing on patients with earlier-stage non ...

Q4 2024 Earnings Call Transcript February 14, 2025 Moderna, Inc. misses on earnings expectations. Reported EPS is $-2.91 EPS, ...

Moderna is now expecting 2025 research and development costs of about $4.1 billion and selling, general and administrative costs of about $1.1 billion. Cost of sales is expected to come to about $1.2 ...

Equity markets performed well in January, as they often do, but as the dust settles on that early-year run, the strategy for ...

Moderna ( NASDAQ: MRNA) Q4 2024 Earnings Conference Call February 14, 2025 8:00 AM ET Lavina Talukdar - Senior Vice President, Investor Relations Stephane Bancel - Chief Executive Officer Jamey Mock - ...

The Keytruda-Lenvima regimen ... such as Kelun Biotech-partnered TROP2 antibody-drug conjugate sac-TMT and the Moderna-partnered personalized cancer vaccine mRNA-4157 (V940).

The most talked about and market moving research calls around Wall Street are now in one place. Here are today's research ...

slashed the risk of recurrence or death in melanoma patients by 49% compared to Keytruda alone. Moderna has several other exciting candidates in phase 2 studies. Though the stock remains down ...